Infigratinib has been approved in the same setting, having obtained an ORR of 18.8% and a disease control rate of 83.3%.19 In a phase II trial, 5 patients with FGFR2 mutations were included and all had stable disease.20 Moreover, futibatinib was granted an accelerated approval for treatment of locally advanced/metastatic iCCA with an FGFR2 gene rearrangement or fusion, based on the phase II FOENIX-CCA2 trial.21 In this single-arm trial, 103 iCCA patients harboring FGFR2 fusion/rearrangements and disease progression after 1 or more prior treatments received futibatinib at 20 mg once daily. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.